Latest News and Press Releases

DUBLIN, Ireland and TREVOSE, Pa., July 01, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

DUBLIN, Ireland and TREVOSE, Pa., June 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

Scott Wilhoit Promoted to Chief Commercial Officer Marcy Nanus Appointed Vice President of Corporate Affairs DUBLIN, Ireland and TREVOSE, Pa., June 04, 2019 (GLOBE NEWSWIRE) -- Strongbridge...

DUBLIN, Ireland and TREVOSE, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

~ Results Demonstrate Long-term Treatment with KEVEYIS is Efficacious and Provides Durable Reduction in Attack Frequency and Severity in Patients with PPP ~ DUBLIN, Ireland and TREVOSE, Pa., May 09,...

~ Following Type C Meeting with the U.S. Food & Drug Administration (FDA), Strongbridge Plans to Submit its New Drug Application (NDA) for RECORLEV™ (levoketoconazole) in the Third Quarter of...

DUBLIN, Ireland and TREVOSE, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

DUBLIN, Ireland and TREVOSE, Pa., April 24, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

DUBLIN, Ireland and TREVOSE, Pa., April 15, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

~ Subgroup Analysis of Patients with Comorbid Diabetes Mellitus and Cushing’s Syndrome Presented at Annual Meeting of the Endocrine Society (ENDO) Shows Potential Clinical Benefit of Treatment with...